Frequency of JAK2 Mutations in Patients with Suspected Myeloproliferative Neoplasms

被引：0
|
作者：
Judd, A. [1 ]
Chabot-Richards, D. [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2019年 / 21卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H005
引用
收藏
页码：1138 / 1138
页数：1
相关论文
共 50 条
  • [1] JAK2 and MPL mutations in myeloproliferative neoplasms
    Koppikar, Priya
    Levine, Ross L.
    ACTA HAEMATOLOGICA, 2008, 119 (04) : 218 - 225
  • [2] JAK2 mutations and clinical practice in myeloproliferative neoplasms
    Tefferi, Ayalew
    CANCER JOURNAL, 2007, 13 (06): : 366 - 371
  • [3] JAK2 mutations in myeloproliferative neoplasms: a 2008 update
    Guerin, Estelle
    Praloran, Vincent
    Lippert, Eric
    HEMATOLOGIE, 2008, 14 (05): : 368 - 377
  • [4] Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
    Passamonti, Francesco
    Maffioli, Margherita
    Caramazza, Domenica
    Cazzola, Mario
    ONCOTARGET, 2011, 2 (06) : 485 - 490
  • [5] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Tanja Belcic Mikic
    Tadej Pajic
    Matjaz Sever
    Scientific Reports, 9
  • [6] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Mikic, Tanja Belcic
    Pajic, Tadej
    Sever, Matjaz
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [7] CALR, JAK2 Exon 14, and JAK2 Exon 12 mutations profiles in patients with Myeloproliferative Neoplasms
    Yasin, Elrashed B.
    Alkhatabi, Heba
    Ahmedah, Hanadi Talal
    Felimban, Raed
    Tayeb, Hossam H.
    Alalla, Zainab Jawdat
    Abdulqayoom, Heyam Abdulsamad
    Alserihi, Raed
    BIOSCIENCE RESEARCH, 2021, 18 (02): : 1699 - 1707
  • [8] Myeloproliferative Neoplasms: The Era of JAK2 Mutations and More...
    Saxena, Renu
    Gupta, Sanjeev Kumar
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 4 - 5
  • [9] Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
    Nangalia, J.
    Massie, C. E.
    Baxter, E. J.
    Nice, F. L.
    Gundem, G.
    Wedge, D. C.
    Avezov, E.
    Li, J.
    Kollmann, K.
    Kent, D. G.
    Aziz, A.
    Godfrey, A. L.
    Hinton, J.
    Martincorena, I.
    Van Loo, P.
    Jones, A. V.
    Guglielmelli, P.
    Tarpey, P.
    Harding, H. P.
    Fitzpatrick, J. D.
    Goudie, C. T.
    Ortmann, C. A.
    Loughran, S. J.
    Raine, K.
    Jones, D. R.
    Butler, A. P.
    Teague, J. W.
    O'Meara, S.
    McLaren, S.
    Bianchi, M.
    Silber, Y.
    Dimitropoulou, D.
    Bloxham, D.
    Mudie, L.
    Maddison, M.
    Robinson, B.
    Keohane, C.
    Maclean, C.
    Hill, K.
    Orchard, K.
    Tauro, S.
    Du, M-Q
    Greaves, M.
    Bowen, D.
    Huntly, B. J. P.
    Harrison, C. N.
    Cross, N. C. P.
    Ron, D.
    Vannucchi, A. M.
    Papaemmanuil, E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25): : 2391 - 2405
  • [10] JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
    O Kilpivaara
    R L Levine
    Leukemia, 2008, 22 : 1813 - 1817
12345